NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT02516241,Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer,https://clinicaltrials.gov/study/NCT02516241,,ACTIVE_NOT_RECRUITING,"A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Stage IV Urothelial Cancer",YES,Urothelial Cancer,DRUG: MEDI4736 (Durvalumab)|DRUG: Tremelimumab|DRUG: Cisplatin|DRUG: Carboplatin|DRUG: Gemcitabine,"To Assess the Efficacy of Durvalumab + Tremelimumab Combination Therapy Versus SoC in Terms of OS in Full Analysis Set, The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique., From randomization date until death due to any cause, assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).|To Assess the Efficacy of Durvalumab Monotherapy Versus SoC in Terms of OS in PD-L1-High Analysis Set, The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique., From randomization date until death due to any cause, assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).","OS, Full Analysis Set - Durvalumab Monotherapy vs SoC, The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique., From randomization date until death due to any cause, assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).|OS, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC, The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique., From randomization date until death due to any cause, assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).|OS, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy, The OS was defined as the time from the date of randomization until death due to any cause (ie, date of death or censoring - date of randomization + 1). Any participant not known to have died at the time of analysis were censored based on the last recorded date on which the participant was known to be alive. Median OS was calculated using the Kaplan-Meier technique., From randomization date until death due to any cause, assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).|Alive at 24 Months (OS24), Full Analysis Set, Alive at 24 months (OS24) is defined as the Kaplan-Meier estimate of OS at 24 months., From randomization date until death due to any cause, assessed up to 24 months or the data cut-off date (27JAN2020).|Alive at 24 Months (OS24), PD-L1-High Analysis Set, Alive at 24 months (OS24) is defined as the Kaplan-Meier estimate of OS at 24 months., From randomization date until death due to any cause, assessed up to 24 months or the data cut-off date (27JAN2020).|Alive at 24 Months (OS24), PD-L1-Low/Negative Analysis Set, Alive at 24 months (OS24) is defined as the Kaplan-Meier estimate of OS at 24 months., From randomization date until death due to any cause, assessed up to 24 months or the data cut-off date (27JAN2020).|PFS, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC, Progression free survival (PFS) (per RECIST 1.1, as assessed by investigator) was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomized therapy or receives another anticancer therapy prior to progression.

Median PFS was calculated using the Kaplan-Meier technique., Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).|PFS, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC, Progression free survival (PFS) (per RECIST 1.1, as assessed by investigator) was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomized therapy or receives another anticancer therapy prior to progression.

Median PFS was calculated using the Kaplan-Meier technique., Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).|PFS, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy, Progression free survival (PFS) (per RECIST 1.1, as assessed by investigator) was defined as the time from the date of randomization until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient withdraws from randomized therapy or receives another anticancer therapy prior to progression.

Median PFS was calculated using the Kaplan-Meier technique., Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).|Alive and Progression-free at 12 Months (APF12), Full Analysis Set, Alive and progression-free at 12 months (APF12) was defined as the Kaplan-Meier estimate of PFS (per RECIST 1.1 as assessed by investigator) at 12 months., Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 12 months or the data cut-off date (27JAN2020).|Alive and Progression-free at 12 Months (APF12), PD-L1-High Analysis Set, Alive and progression-free at 12 months (APF12) was defined as the Kaplan-Meier estimate of PFS (per RECIST 1.1 as assessed by investigator) at 12 months., Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 12 months or the data cut-off date (27JAN2020).|Alive and Progression-free at 12 Months (APF12), PD-L1-Low/Negative Analysis Set, Alive and progression-free at 12 months (APF12) was defined as the Kaplan-Meier estimate of PFS (per RECIST 1.1 as assessed by investigator) at 12 months., Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 12 months or the data cut-off date (27JAN2020).|PFS2, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC, Time from randomization to second progression or death (PFS2) was defined as the time from the date of randomization to the earliest of the progression event subsequent to first subsequent therapy or death (ie, date of PFS2 event or censoring - date of randomization +1).

Median PFS2 was calculated using the Kaplan-Meier technique., Tumour scans performed at baseline then every 8 weeks since randomization until first confirmed disease progression, disease then assessed per local practice until 2nd progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).|PFS2, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC, Time from randomization to second progression or death (PFS2) was defined as the time from the date of randomization to the earliest of the progression event subsequent to first subsequent therapy or death (ie, date of PFS2 event or censoring - date of randomization +1).

Median PFS2 was calculated using the Kaplan-Meier technique., Tumour scans performed at baseline then every 8 weeks since randomization until first confirmed disease progression, disease then assessed per local practice until 2nd progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).|PFS2, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy, Time from randomization to second progression or death (PFS2) was defined as the time from the date of randomization to the earliest of the progression event subsequent to first subsequent therapy or death (ie, date of PFS2 event or censoring - date of randomization +1).

Median PFS2 was calculated using the Kaplan-Meier technique., Tumour scans performed at baseline then every 8 weeks since randomization until first confirmed disease progression, disease then assessed per local practice until 2nd progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).|Objective Response Rate (ORR), Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC, Objective response rate ORR (per RECIST 1.1 as assessed by investigator) is defined as the number (%) of patients with at least 1 visit response of CR or PR., Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).|Objective Response Rate (ORR), PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC, Objective response rate ORR (per RECIST 1.1 as assessed by investigator) is defined as the number (%) of patients with at least 1 visit response of CR or PR., Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).|Objective Response Rate (ORR), PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy, Objective response rate ORR (per RECIST 1.1 as assessed by investigator) is defined as the number (%) of patients with at least 1 visit response of CR or PR., Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).|Objective Response Rate (ORR) Based on BICR Assessment According to RECIST 1.1 - Responses Are Confirmed - Durvalumab Cisplatin Ineligible Population, Objective response rate ORR (per RECIST 1.1 as assessed by investigator) is defined as the number (%) of patients with at least 1 visit response of CR or PR.

unconfirmed responses are excluded., Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (01NOV2017, a maximum of 3 years).|Disease Control Rate (DCR) at 6 Months, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC, Disease control rate (DCR) at 6 months is defined as the percentage of patients who have a best objective response (BoR) of CR or PR, or who have demonstrated SD for a minimum interval of 24 weeks (-7 days, i.e., 161 days), following the start of study treatment., Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 6 months or the data cut-off date (27JAN2020).|Disease Control Rate (DCR) at 6 Months, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC, Disease control rate (DCR) at 6 months is defined as the percentage of patients who have a best objective response (BoR) of CR or PR, or who have demonstrated SD for a minimum interval of 24 weeks (-7 days, i.e., 161 days), following the start of study treatment., Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 6 months or the data cut-off date (27JAN2020).|Disease Control Rate (DCR) at 6 Months, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy, Disease control rate (DCR) at 6 months is defined as the percentage of patients who have a best objective response (BoR) of CR or PR, or who have demonstrated SD for a minimum interval of 24 weeks (-7 days, i.e., 161 days), following the start of study treatment., Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 6 months or the data cut-off date (27JAN2020).|Disease Control Rate (DCR) at 12 Months, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC, Disease control rate (DCR) at 12 months is defined as the percentage of patients who have a best objective response (BoR) of CR or PR, or who have demonstrated SD for a minimum interval of 48 weeks (-7 days, i.e., 329 days), following the start of study treatment., Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 12 months or the data cut-off date (27JAN2020)|Disease Control Rate (DCR) at 12 Months, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Monotherapy vs SoC, Disease control rate (DCR) at 12 months is defined as the percentage of patients who have a best objective response (BoR) of CR or PR, or who have demonstrated SD for a minimum interval of 48 weeks (-7 days, i.e., 329 days), following the start of study treatment., Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 12 months or the data cut-off date (27JAN2020).|Disease Control Rate (DCR) at 12 Months, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy Versus SoC and Durvalumab + Tremelimumab Combination Therapy Versus Durvalumab Monotherapy, Disease control rate (DCR) at 12 months is defined as the percentage of patients who have a best objective response (BoR) of CR or PR, or who have demonstrated SD for a minimum interval of 48 weeks (-7 days, i.e., 329 days), following the start of study treatment., Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to 12 months or the data cut-off date (27JAN2020).|Duration of Response (DoR), Full Analysis Set, Duration of response (DoR) (per RECIST 1.1 as assessed by investigator) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1)., Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).|Duration of Response (DoR), PD-L1-High Analysis Set, Duration of response (DoR) (per RECIST 1.1 as assessed by investigator) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1)., Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).|Duration of Response (DoR), PD-L1-Low/Negative Analysis Set, Duration of response (DoR) (per RECIST 1.1 as assessed by investigator) was defined as the time from the date of first documented response until the first date of documented progression or death in the absence of disease progression (i.e. date of PFS event or censoring - date of first response + 1)., Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).|Serum Concentrations of Durvalumab, Pharmacokinetic Analysis Set, Blood samples were collected to determine the serum concentration of durvalumab., Pre-dose and within 1 hour after end of infusion at Week 0, 12 and 24, pre-dose at week 4, and at follow-up Month 3.|Serum Concentrations of Tremelimumab, Pharmacokinetic Analysis Set, Blood samples were collected to determine the serum concentration of tremelimumab., Pre-dose and within 1 hour after end of infusion at Week 0, 12 and 24, pre-dose at week 4, and at follow-up Month 3.|Number of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab, Safety Analysis Set - ADA Evaluable Patients, Serum Samples will be measured for the presence of ADAs and ADA-neutralizing antibodies for Durvalumab using validated assays. Tiered analysis will be performed to include screening, confirmatory, and titer assay components, and positive-negative cut points previously statistically determined from drug-naïve validation samples will be used. Persistently positive is defined as having at least 2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. The category may include patients meeting these criteria who are ADA positive at baseline., At week 0, 4, 12 and 24, and at follow-up Month 3.|Number of Participants With Anti-Drug Antibody (ADA) Response to Tremelimumab, Safety Analysis Set - ADA Evaluable Patients, Serum Samples will be measured for the presence of ADAs and ADA-neutralizing antibodies for Tremelimumab using validated assays. Tiered analysis will be performed to include screening, confirmatory, and titer assay components, and positive-negative cut points previously statistically determined from drug-naïve validation samples will be used. Persistently positive is defined as having at least 2 post-baseline ADA positive measurements with at least 16 weeks (112 days) between the first and last positive measurements, or an ADA positive result at the last available assessment. Transiently positive is defined as having at least one post-baseline ADA positive measurement and not fulfilling the conditions for persistently positive. The category may include patients meeting these criteria who are ADA positive at baseline., At week 0, 4, 12 and at follow-up Month 3.|Change From Baseline in FACT-BL (Derived NFBlSI-18 Score, FACT-BL TOI, and FACT-BL Total Score) by MMRM Analysis, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC, the change from baseline in the following total/index scores will be evaluated as secondary endpoints: FACT-BL TOI (refer to as TOI), FACT-BL Total score, and NFBlSI-18 score.

All the 5 subscales (PWB (0-28), FWB (0-28), EWB (0-24), SWB (0-28), and BlCS(0-48)) are summed as the FACT-BL total score (range 0-156), while the sum of PWB, FWB and BICS constitutes the FACT-BL TOI (range 0-104).

NFBlSI-18 (range 0-72) is based on the scores of 16 items (GP4, C2, BL1, GP3, GE6, GE1, C6, BL5, GF5, GP2, GP1, GP6, C3, GP5, GF3, GF7) and 2 extra items ""I feel weak all overall"" and ""I feel light-headed (dizzy)"". The range of each item is 0-4.

Higher score represent worse outcome., At baseline then every 8 weeks until second progression/death, whichever comes first. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).|Change From Baseline in FACT-BL (Derived NFBlSI-18 Score, FACT-BL TOI, and FACT-BL Total Score) by MMRM Analysis, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC, the change from baseline in the following total/index scores will be evaluated as secondary endpoints: FACT-BL TOI (refer to as TOI), FACT-BL Total score, and NFBlSI-18 score.

All the 5 subscales (PWB (0-28), FWB (0-28), EWB (0-24), SWB (0-28), and BlCS(0-48)) are summed as the FACT-BL total score (range 0-156), while the sum of PWB, FWB and BICS constitutes the FACT-BL TOI (range 0-104).

NFBlSI-18 (range 0-72) is based on the scores of 16 items (GP4, C2, BL1, GP3, GE6, GE1, C6, BL5, GF5, GP2, GP1, GP6, C3, GP5, GF3, GF7) and 2 extra items ""I feel weak all overall"" and ""I feel light-headed (dizzy)"". The range of each item is 0-4.

Higher score represent worse, At baseline then every 8 weeks until second progression/death, whichever comes first. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).|Change From Baseline in FACT-BL (Derived NFBlSI-18 Score, FACT-BL TOI, and FACT-BL Total Score) by MMRM Analysis, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC, the change from baseline in the following total/index scores will be evaluated as secondary endpoints: FACT-BL TOI (refer to as TOI), FACT-BL Total score, and NFBlSI-18 score.

All the 5 subscales (PWB (0-28), FWB (0-28), EWB (0-24), SWB (0-28), and BlCS(0-48)) are summed as the FACT-BL total score (range 0-156), while the sum of PWB, FWB and BICS constitutes the FACT-BL TOI (range 0-104).

NFBlSI-18 (range 0-72) is based on the scores of 16 items (GP4, C2, BL1, GP3, GE6, GE1, C6, BL5, GF5, GP2, GP1, GP6, C3, GP5, GF3, GF7) and 2 extra items ""I feel weak all overall"" and ""I feel light-headed (dizzy)"". The range of each item is 0-4.

Higher score represent worse, At baseline then every 8 weeks until second progression/death, whichever comes first. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).|Improvement in Fatigue and Deterioration in Pain Per FACT-BL, Full Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC, Fatigue will be based on the question of ""I have a lack of energy"" and pain will be based on the question of ""I have pain"", according to GP1 and GP4 in PWB, respectively.

Improvement in fatigue is defined at least 1 point improvement from baseline using GP1 of FACT-BL.

Deterioration in pain is defined as at least 1 point deterioration from baseline using GP4 of FACT-BL., At baseline then every 8 weeks until second progression/death, whichever comes first. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).|Improvement in Fatigue and Deterioration in Pain Per FACT-BL, PD-L1-High Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC, Fatigue will be based on the question of ""I have a lack of energy"" and pain will be based on the question of ""I have pain"", according to GP1 and GP4 in PWB, respectively.

Improvement in fatigue is defined at least 1 point improvement from baseline using GP1 of FACT-BL.

Deterioration in pain is defined as at least 1 point deterioration from baseline using GP4 of FACT-BL., At baseline then every 8 weeks until second progression/death, whichever comes first. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).|Improvement in Fatigue and Deterioration in Pain Per FACT-BL, PD-L1-Low/Negative Analysis Set -Durvalumab + Tremelimumab Combination Therapy vs SoC and Durvalumab Mono Therapy vs SoC, Fatigue will be based on the question of ""I have a lack of energy"" and pain will be based on the question of ""I have pain"", according to GP1 and GP4 in PWB, respectively.

Improvement in fatigue is defined at least 1 point improvement from baseline using GP1 of FACT-BL.

Deterioration in pain is defined as at least 1 point deterioration from baseline using GP4 of FACT-BL., At baseline then every 8 weeks until second progression/death, whichever comes first. Assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).",,AstraZeneca,,ALL,"ADULT, OLDER_ADULT",PHASE3,1126,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,D419BC00001,2015-11-02,2020-01-27,2025-12-31,2015-08-05,2021-05-13,2025-03-25,"Research Site, Los Angeles, California, 90095, United States|Research Site, Stanford, California, 94305, United States|Research Site, Aurora, Colorado, 80045, United States|Research Site, New Haven, Connecticut, 06520, United States|Research Site, Tampa, Florida, 33612, United States|Research Site, Atlanta, Georgia, 30322, United States|Research Site, Louisville, Kentucky, 40202, United States|Research Site, Boston, Massachusetts, 02215, United States|Research Site, Ann Arbor, Michigan, 48109, United States|Research Site, Detroit, Michigan, 48201, United States|Research Site, Omaha, Nebraska, 68130, United States|Research Site, New York, New York, 10021, United States|Research Site, New York, New York, 10029, United States|Research Site, Memphis, Tennessee, 38120, United States|Research Site, Nashville, Tennessee, 37203, United States|Research Site, Seattle, Washington, 98101, United States|Research Site, Box Hill, 3128, Australia|Research Site, Elizabeth Vale, 5112, Australia|Research Site, Macquarie University, 2109, Australia|Research Site, St Leonards, 2065, Australia|Research Site, Waratah, 2298, Australia|Research Site, Linz, 4010, Austria|Research Site, Wien, 1090, Austria|Research Site, Wien, 1140, Austria|Research Site, Brussels, 1000, Belgium|Research Site, Bruxelles, 1200, Belgium|Research Site, Leuven, 3000, Belgium|Research Site, Liège, 4000, Belgium|Research Site, Barretos, 14784-400, Brazil|Research Site, Belo Horizonte, 30380-472, Brazil|Research Site, Ijui, 98700-000, Brazil|Research Site, Itajai, 88301-220, Brazil|Research Site, Porto Alegre, 90035-003, Brazil|Research Site, Porto Alegre, 90610-000, Brazil|Research Site, Porto Alegre, 91350-200, Brazil|Research Site, Rio de Janeiro, 20231-050, Brazil|Research Site, Rio de Janeiro, 22793-080, Brazil|Research Site, Sao Paulo, 01209-000, Brazil|Research Site, Sao Paulo, 01321-001, Brazil|Research Site, Sao Paulo, 01509-900, Brazil|Research Site, São José do Rio Preto, 15090-000, Brazil|Research Site, Calgary, Alberta, T2N 4N2, Canada|Research Site, Edmonton, Alberta, T6G 1Z2, Canada|Research Site, Kelowna, British Columbia, V1Y 5L3, Canada|Research Site, Vancouver, British Columbia, V5Z 4E6, Canada|Research Site, Halifax, Nova Scotia, B3H 1V7, Canada|Research Site, Hamilton, Ontario, L8V 5C2, Canada|Research Site, Newmarket, Ontario, L3Y 2P9, Canada|Research Site, Oshawa, Ontario, L1G 2B9, Canada|Research Site, Ottawa, Ontario, K1H 1C4, Canada|Research Site, Toronto, Ontario, M4N 3M5, Canada|Research Site, Toronto, Ontario, M5G 2M9, Canada|Research Site, Sherbrooke, Quebec, J1H 5N4, Canada|Research Site, Quebec, G1R 3S1, Canada|Research Site, Beijing, 100034, China|Research Site, Beijing, 100039, China|Research Site, Beijing, 100191, China|Research Site, Changchun, 130012, China|Research Site, Changsha, 410013, China|Research Site, Chongqing, 400038, China|Research Site, Hangzhou, 310009, China|Research Site, Hangzhou, 310014, China|Research Site, Nanjing, 210008, China|Research Site, Shanghai, 200000, China|Research Site, Shanghai, 200032, China|Research Site, Shanghai, 200072, China|Research Site, Shanghai, 200080, China|Research Site, Shanghai, 200127, China|Research Site, Shenyang, 110001, China|Research Site, Tianjin, 300211, China|Research Site, Xi'an, 710061, China|Research Site, Xiamen, 361003, China|Research Site, Herlev, 2730, Denmark|Research Site, København Ø, 2100, Denmark|Research Site, Odense C, 5000, Denmark|Research Site, Århus C, 8000, Denmark|Research Site, Bordeaux, 33000, France|Research Site, Bordeaux, 33076, France|Research Site, Caen Cedex, 14076, France|Research Site, Lyon Cedex 08, 69008, France|Research Site, Marseille cedex 09, 13273, France|Research Site, Paris Cedex 10, 75475, France|Research Site, Poitiers Cedex, 86021, France|Research Site, Suresnes Cedex, 92151, France|Research Site, Toulouse, 31059, France|Research Site, Villejuif, 94805, France|Research Site, Düsseldorf, 40225, Germany|Research Site, Erlangen, 91054, Germany|Research Site, Hannover, 30625, Germany|Research Site, Heidelberg, 69120, Germany|Research Site, Jena, 07747, Germany|Research Site, München, 81675, Germany|Research Site, Münster, 48149, Germany|Research Site, Athens, 11528, Greece|Research Site, Athens, 14564, Greece|Research Site, Heraklion, 71110, Greece|Research Site, Holargos, Athens, 155 62, Greece|Research Site, Maroussi, Athens, 15125, Greece|Research Site, Patras, 26500, Greece|Research Site, Thessaloniki, 56 429, Greece|Research Site, Haifa, 31096, Israel|Research Site, Jerusalem, 91120, Israel|Research Site, Petach-Tikva, 4941492, Israel|Research Site, Ramat Gan, 5265601, Israel|Research Site, Zerifin, 70300, Israel|Research Site, Arezzo, 52100, Italy|Research Site, Meldola, 47014, Italy|Research Site, Milano, 20132, Italy|Research Site, Milano, 20133, Italy|Research Site, Napoli, 80131, Italy|Research Site, Orbassano, 10043, Italy|Research Site, Pavia, 27100, Italy|Research Site, Roma, 00152, Italy|Research Site, San Giovanni Rotondo, 71013, Italy|Research Site, Akita-shi, 010-8543, Japan|Research Site, Bunkyo-ku, 113-8603, Japan|Research Site, Fukuoka-shi, 811-1347, Japan|Research Site, Hakata-shi, 812-0033, Japan|Research Site, Hirosaki-shi, 036-8563, Japan|Research Site, Hiroshima-shi, 730-8518, Japan|Research Site, Izumo-shi, 693-8501, Japan|Research Site, Kagoshima-shi, 890-8520, Japan|Research Site, Kanazawa-shi, 920-8641, Japan|Research Site, Kita-gun, 761-0793, Japan|Research Site, Kobe-shi, 650-0047, Japan|Research Site, Koshigaya-shi, 343-8555, Japan|Research Site, Koto-ku, 135-8550, Japan|Research Site, Kumamoto-shi, 860-0008, Japan|Research Site, Kyoto-shi, 606-8507, Japan|Research Site, Matsuyama-shi, 791-0280, Japan|Research Site, Morioka-shi, 028-3695, Japan|Research Site, Nagasaki-shi, 852-8501, Japan|Research Site, Nagoya-shi, 460-0001, Japan|Research Site, Nagoya-shi, 466-8560, Japan|Research Site, Osaka-shi, 541-8567, Japan|Research Site, Osaka-shi, 545-8586, Japan|Research Site, Osakasayama-shi, 589-8511, Japan|Research Site, Saga-shi, 840-8571, Japan|Research Site, Sagamihara-shi, 252-0315, Japan|Research Site, Sakura-shi, 285-8741, Japan|Research Site, Sapporo-shi, 060-8648, Japan|Research Site, Suita-shi, 565-0871, Japan|Research Site, Takatsuki-shi, 569-8686, Japan|Research Site, Yokohama-shi, 232-0024, Japan|Research Site, Yokohama-shi, 236-0004, Japan|Research Site, Incheon, 21565, Korea, Republic of|Research Site, Seongnam-si, 13620, Korea, Republic of|Research Site, Seoul, 02841, Korea, Republic of|Research Site, Seoul, 03080, Korea, Republic of|Research Site, Seoul, 03722, Korea, Republic of|Research Site, Seoul, 05505, Korea, Republic of|Research Site, Seoul, 6351, Korea, Republic of|Research Site, Guadalajara, 44280, Mexico|Research Site, León, 37000, Mexico|Research Site, Mexico, D.F, 01120, Mexico|Research Site, Mexico, 06760, Mexico|Research Site, Monterrey, 64460, Mexico|Research Site, México, 04739, Mexico|Research Site, Amsterdam, 1066 CX, Netherlands|Research Site, Amsterdam, 1081 HV, Netherlands|Research Site, Breda, 4819 EV, Netherlands|Research Site, Enschede, 7512 KZ, Netherlands|Research Site, Groningen, 9713 GZ, Netherlands|Research Site, Leiden, 2333 ZA, Netherlands|Research Site, Maastricht, 6229 HX, Netherlands|Research Site, Nijmegen, 6525 GA, Netherlands|Research Site, Gdańsk, 80-214, Poland|Research Site, Gdańsk, 80-462, Poland|Research Site, Gdynia, 81-519, Poland|Research Site, Gliwice, 44-101, Poland|Research Site, Olsztyn, 10-228, Poland|Research Site, Otwock, 05-400, Poland|Research Site, Szczecin, 70-111, Poland|Research Site, Warszawa, 02-781, Poland|Research Site, Lisboa, 1649-035, Portugal|Research Site, Loures, 2674-514, Portugal|Research Site, Porto, 4099-001, Portugal|Research Site, Moscow, 105229, Russian Federation|Research Site, Moscow, 115478, Russian Federation|Research Site, Murmansk, 183047, Russian Federation|Research Site, Nizhnyi Novgorod, 603001, Russian Federation|Research Site, Obninsk, 249036, Russian Federation|Research Site, Omsk, 644013, Russian Federation|Research Site, Saint Petersburg, 191015, Russian Federation|Research Site, Saint-Petersburg, 197758, Russian Federation|Research Site, St. Petersburg, 194354, Russian Federation|Research Site, St. Petersburg, 199178, Russian Federation|Research Site, St.Petersburg, 191014, Russian Federation|Research Site, Ufa, 450054, Russian Federation|Research Site, Yaroslavl, 150054, Russian Federation|Research Site, Badajoz, 06008, Spain|Research Site, Badalona, 08916, Spain|Research Site, Barcelona, 08003, Spain|Research Site, Barcelona, 08243, Spain|Research Site, Elche(Alicante), 03202, Spain|Research Site, Madrid, 08035, Spain|Research Site, Madrid, 28007, Spain|Research Site, Madrid, 28040, Spain|Research Site, Madrid, 28041, Spain|Research Site, Madrid, 28050, Spain|Research Site, Pozuelo de Alarcon, 28223, Spain|Research Site, Santiago de Compostela, 15706, Spain|Research Site, Sevilla, 41013, Spain|Research Site, Kaohsiung, Taiwan|Research Site, Taichung, 00407, Taiwan|Research Site, Tainan, 704, Taiwan|Research Site, Taipei, 10002, Taiwan|Research Site, Taipei, 112, Taiwan|Research Site, Taoyuan City, 333, Taiwan|Research Site, Ankara, 06230, Turkey|Research Site, Edirne, 22030, Turkey|Research Site, Izmir, 35100, Turkey|Research Site, Cambridge, CB2 0QQ, United Kingdom|Research Site, Cardiff., CF14 2TL, United Kingdom|Research Site, Glasgow, G12 0YN, United Kingdom|Research Site, Leeds, LS9 7TF, United Kingdom|Research Site, London, E1 1BB, United Kingdom|Research Site, London, SE1 9RT, United Kingdom|Research Site, Manchester, M20 4BX, United Kingdom|Research Site, Sheffield, S10 2SJ, United Kingdom|Research Site, Southampton, SO16 6YD, United Kingdom|Research Site, Wirral, CH63 4JY, United Kingdom","Study Protocol, https://cdn.clinicaltrials.gov/large-docs/41/NCT02516241/Prot_000.pdf|Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/41/NCT02516241/SAP_001.pdf"
